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Background: This study evaluated the effects of aclidinium bromide, a long-acting muscarinic antagonist indicated
for maintenance treatment of chronic obstructive pulmonary disease (COPD), on exercise endurance, dyspnea, lung
hyperinflation, and physical activity.
Methods: In this randomized, double-blind, crossover study, patients with stable COPD and moderate-to-severe
airflow limitation received aclidinium 400 μg twice daily or placebo via Genuair®/Pressair®a for 3 weeks (2-week
washout between treatment periods). The primary endpoint was change from baseline to Week 3 in endurance
time, measured by constant work rate cycle ergometry testing at 75% peak incremental work rate. Changes from
baseline in intensity of exertional dyspnea (Borg CR10 Scale®) and trough inspiratory capacity were secondary
endpoints. Additional endpoints included changes from baseline in other spirometric, plethysmographic, and physical
activity (assessed by objective accelerometer measurement) parameters. Efficacy endpoints were analyzed using an
analysis of covariance model.
Results: In total, 112 patients were randomized and treated (mean age 60.3 years; mean post-bronchodilator
forced expiratory volume in 1 s 1.7 L [56.7% predicted]; mean endurance time 485.7 s). After 3 weeks, endurance
time was significantly increased with aclidinium versus placebo (treatment difference 58.5 s; p < 0.05). At Week 3,
aclidinium significantly reduced dyspnea intensity at isotime during exercise (treatment difference −0.63; p < 0.05)
and improved trough inspiratory capacity (treatment difference 78 mL; p < 0.05) versus placebo. Significant
improvements in spirometric, plethysmographic, and some physical activity parameters were observed with aclidinium
versus placebo.
Conclusions: These results suggest that aclidinium significantly improves exercise endurance, exertional dyspnea,
hyperinflation, and physical activity in patients with COPD.
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Exercise limitation, driven predominantly by activity-related
dyspnea, is an important feature of chronic obstructive pul-
monary disease (COPD) that compromises daily living
activities, leads to physical deconditioning, and contributes
to a reduced perceived quality of life [1-6]. Lung hyperinfla-
tion is thought to represent a mechanical link between the
characteristic expiratory airflow impairment, dyspnea, and
exercise capacity [5,6].
In patients with COPD, expiratory flow limitation and
reduced lung elastic recoil result in air trapping and an
increased end-expiratory lung volume (EELV) compared
with healthy individuals [5-8]. During physical activity,
acute increases in EELV (dynamic hyperinflation) occur
and dyspnea is exacerbated, which can lead to avoidance
of activity [5-8]. Alleviating hyperinflation and improving
dyspnea, exercise tolerance, and levels of physical activity
are important therapeutic goals in the management of
COPD [9].
While there is a large body of clinical evidence regard-
ing the effect of long-acting bronchodilators, including
long-acting muscarinic antagonists (LAMAs), on exer-
cise endurance [10-13], little is known about the transla-
tion of such improvements into changes in everyday
physical activity. Aclidinium bromide is a novel LAMA
recently approved, at a dose of 400 μg twice daily
(BID), as a treatment for COPD [14,15]. In a previous
study, aclidinium 200 μg once daily (QD) significantly
improved exercise endurance time, exertional dyspnea,
and static hyperinflation versus placebo in patients
with COPD [16]. Here we report results from a ran-
domized, double-blind Phase IIIb crossover study to
evaluate the effect of aclidinium 400 μg BID on cycling
exercise endurance, exertional dyspnea, and lung
hyperinflation in patients with COPD. A thorough
profiling of lung volumes and objective measures of
daily physical activity are also included.Figure 1 Study design. Symptom-limited incremental cycle exercise test
Constant work rate exercise testing at 75% of symptom-limited maximum
at 3 h post-dose at Visits 2 and 4. Spirometry was performed pre-dose at
performed pre-dose at Visits 1 and 3 (baseline), and at 2 h post-dose at VMethods
Study design and treatment
This Phase IIIb randomized, double-blind, crossover study
was conducted between November 2011 and June 2012 at
14 sites in Germany, Spain, and the UK (clinicaltrials.gov
identifier: NCT01471171). Following screening and a 2- to
3-week run-in period (including a visit 1 week before Visit 1
to familiarize patients with study procedures), patients were
randomized (1:1; Visit 1) to aclidinium 400 μg (metered
dose; equivalent to aclidinium 322 μg delivered dose) BID
or placebo, each for 3 weeks in one of two sequences, with
a 2-week washout between treatments (Figure 1).
Aclidinium and matched placebo were administered BID
(09:00 ± 1 h and 21:00 ± 1 h) via a dry powder inhaler
(Genuair®/Pressair®a). Randomization was performed ac-
cording to unique patient identification numbers and a
computer-generated random allocation sequence; pa-
tients and investigators were blinded to treatment allo-
cation throughout the study.
Treatment with other long-acting bronchodilators
was not permitted during the study. Patients were re-
quired to have discontinued treatment with LAMAs at
least 7 days prior to the screening visit. Treatment with
long-acting β2-agonists (LABAs) must have been dis-
continued at least 48 h prior to screening for BID
LABAs and at least 7 days prior to screening for QD
LABAs. Relief medication (salbutamol pressurized
metered dose inhaler 100 μg/puff ) was provided for
symptom control as needed (except ≤6 h prior to lung
function testing at each visit). The following mainten-
ance therapies were also permitted if their use had been
stable for ≥4 weeks prior to study entry: oral sustained-
release theophylline, inhaled corticosteroids, and oral
or parenteral corticosteroids (prednisone ≤10 mg per
day or ≤20 mg every other day). Corticosteroid use was
required to be suspended for ≥6 h prior to lung func-
tion testing at any visit.ing was performed at screening to determine maximum work rate.
work rate was conducted pre-dose at Visits 1 and 3 (baseline), and
Visits 1 and 3 (baseline) and at Visits 2 and 4; plethysmography was
isits 2 and 4. BID, twice daily.
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Patients aged ≥40 years with stable COPD and moderate-
to-severe airflow limitation (post-bronchodilator forced
expiratory volume in 1 s [FEV1] ≥30% and <80% of the
predicted value, and FEV1/forced vital capacity [FVC]
<70% at screening [9]), who were current or former
cigarette smokers (smoking history of ≥10 pack-years) and
had a functional residual capacity (FRC) of ≥120% of the
predicted value at screening were eligible. Severity of dys-
pnea was not a specific inclusion criterion in the study.
Patients with a history of asthma, or any other clinically
significant respiratory, cardiovascular or other systemic con-
dition that may have contributed to dyspnea and exercise
limitation, were not eligible to participate. Additional exclu-
sion criteria included a respiratory tract infection or COPD
exacerbation within 6 weeks prior to screening (within
3 months if exacerbation resulted in hospitalization), a re-
quirement for long-term oxygen therapy (≥15 h/day), an in-
ability to use the study inhaler, and contraindications for
either the use of anticholinergic drugs or cardiopulmonary
exercise testing [17]. Patients who, in the investigator’s opin-
ion, may have needed to start a pulmonary rehabilitation
program during the study and/or patients who started/fin-
ished a pulmonary rehabilitation program within 3 months
prior to the screening visit were also excluded.
A symptom-limited incremental cycle exercise test was
performed at screening to determine the maximum work
rate that patients were able to maintain for ≥30 s. Patients
who cycled <2 min or >20 min during exercise testing at
75% of maximum work rate during the run-in visit or
Visit 1 (pre-randomization) were not permitted to con-
tinue in the study.
Patients could be discontinued from the study at any
time at their own request or in the event of ineligibility,
non-compliance, lack of efficacy, loss to follow-up (non-
attendance), safety concerns (including moderate or severe
COPD exacerbation), or any other reason at the investiga-
tor’s discretion.
The study was approved by the Independent Ethics
Committees at each site (see Additional file 1) and
was conducted in accordance with the Declaration of
Helsinki, International Conference on Harmonisation,
and Good Clinical Practice. Patients provided written
informed consent before participating in any study
procedures.
Study assessments and endpoints
Constant work rate cycle ergometry testing at 75% max-
imum work rate was conducted pre-dose at Day 1 (base-
line) of each treatment period (Visits 1 and 3), and at 3 h
post-dose at Week 3 of each period (Visits 2 and 4). This
consisted of 3 min rest followed by 3 min unloaded cycling
before the constant phase, in which work rate was in-
creased to 75% of maximum work rate and patients wereencouraged to maintain a pedaling rate of 50–70 rotations
per min until symptom limitation. Change from baseline
in exercise endurance time (time from the start of the
loaded test to the point of symptom limitation) to Week 3
was the primary endpoint.
Before exercise, every 2 min during, and at the end
of exercise, patients rated the intensity of their dyspnea
using the Borg CR10 Scale® (perceived exertion, range:
0 = ‘nothing at all’ to 10 = ‘extremely strong/maximal’).
If patients considered the intensity of their dyspnea
to be stronger than ‘extremely strong/maximal’ , they
could use a larger numerical value (‘absolute max-
imum’). During exercise, inspiratory capacity (IC) was
measured spirometrically at the same time points as a
marker of dynamic hyperinflation. Change from base-
line to Week 3 in intensity of dyspnea at isotime (dur-
ation of the shortest exercise test during Visits 1, 2, 3,
and 4) was a secondary study endpoint. Changes from
baseline to Week 3 in IC before exercise, every 2 min
during exercise, at isotime, and at the end of exercise
were additional endpoints. EELV at rest, at isotime,
and at the end of exercise was calculated post-hoc by
subtracting IC at each time point from mean total lung
capacity (TLC) at 2 h post-dose. Oxygen saturation
(SpO2) during exercise was assessed using a pulse
oximeter.
Change from baseline in resting IC at Week 3 was also a
secondary endpoint. Resting IC was assessed spirometri-
cally pre-dose (trough) at each visit, according to Ameri-
can Thoracic Society and European Respiratory Society
guidelines [18,19]. Changes from baseline at Week 3 in
trough FEV1 and FVC were also measured. All spirometry
data were transferred for centralized reading and under-
went a two-step quality-control process. Resting FRC,
residual volume (RV), TLC, and specific airway con-
ductance (sGaw) were assessed by whole-body plethys-
mography, performed pre-dose on Day 1 of each
treatment period, and pre-dose and at 2 h post-dose at
Week 3 of each period.
To assess physical activity, patients wore an armband
device (SenseWear Pro3®, BodyMedia Inc., Pittsburgh, PA,
USA) day and night (excluding time spent for personal hy-
giene purposes) for 7 days prior to the start of, and during
the last week of, each treatment period. Changes from
baseline in steps per day, minutes of at least moderate ac-
tivity (>3 metabolic equivalents) per day, mean daily active
energy expenditure >3 metabolic equivalents (kcal per
day), and mean physical activity level (PAL; total energy
expenditure divided by resting energy expenditure) [20] at
Week 3 were additional efficacy endpoints. Baseline PAL
values were also used to categorize patients as ‘extremely
inactive’ (PAL <1.40), ‘sedentary’ (PAL 1.40–1.69), and ‘at
least moderately active’ (PAL >1.70) [20]. The frequency
of nocturnal awakenings due to COPD symptoms and
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patient diaries.
Safety assessments included monitoring of adverse events
(AEs) throughout the study, laboratory assessments at
screening and Visit 4, and physical examination, blood
pressure measurement, and 12-lead electrocardiogram at
screening and at Visits 1 and 4.
Statistical analysis
A population of 84 patients was estimated to provide >85%
power to detect a treatment group difference of 120 s for
the primary endpoint. The study, therefore, planned to
screen 170 patients and to randomize 110 patients, allowing
for a 35% screening failure rate and a 20% drop-out rate.
Analyses of efficacy variables were performed on the
intent-to-treat (ITT) population (all randomized patients
who took ≥1 dose of study drug and had ≥1 baseline and
post-dose assessment for the primary endpoint in ≥1 of the
two treatment periods). Efficacy endpoints were analyzed
using an analysis of covariance model with treatment and
period as fixed effects, patients as a random effect, and
baseline values as covariates. Least squares means and
95% confidence intervals (CI) were calculated for treatment
group differences (Δ). Adjustment for multiplicity was per-
formed using a step-down approach: if the comparison be-
tween aclidinium and placebo for the primary endpoint
(exercise endurance time) was significant at the 5% level,
then the secondary endpoints were tested in turn (trough
IC first, intensity of dyspnea at isotime second). EELV at
baseline and at Week 3 was analyzed descriptively. Only
patients with ≥5 days with ≥22 h valid data were included
in the analysis of physical activity parameters [20].
Post-hoc analyses were performed to investigate the re-
lationship between changes from baseline in endurance
time and physical activity, and between changes from
baseline in endurance time and lung volumes (Pearson
Correlation Coefficients). In addition, changes from base-
line in endurance time and trough IC at Week 3, and
physical activity endpoints over the last week of treatment,
were assessed according to baseline PAL. Analyses were
performed using an analysis of covariance model with
treatment and period as fixed effects, patients as a random
effect, and baseline values as covariates.
Patient demographic and baseline characteristics, and
safety outcomes, were summarized descriptively based
on the safety population (all randomized patients who
took ≥1 dose of study drug).
Results
Study population
Of 149 patients screened, 112 were randomized and
treated (safety analysis population) and 110 were included
in the ITT population (Figure 2). The study was completed
by 106 patients; 6 patients discontinued due to AEs.Patient demographics and baseline characteristics are
summarized in Table 1. Details of prior COPD medication
use are shown in Additional file 2. Pre-dose at Visit 1,
49 patients (44.5%) in the ITT population developed dy-
namic hyperinflation during exercise (defined as a >150 mL
decrease from rest in IC [21]).Efficacy endpoints
Exercise endurance, exertional dyspnea, and dynamic
hyperinflation
After 3 weeks of treatment, change from baseline in exer-
cise endurance time was significantly greater with aclidi-
nium compared with placebo (Δ = 58.5 s; 95% CI 9.0, 108.0;
p < 0.05; Figure 3). The percentage change from baseline
was 9.3% with placebo and 18.2% with aclidinium at
Week 3.
Compared with placebo, aclidinium also significantly re-
duced the intensity of dyspnea at isotime from baseline to
Week 3 (Δ = −0.63; 95% CI −1.11, −0.14; p < 0.05) and sig-
nificantly improved dynamic IC from baseline at Week 3
when measured before exercise, at isotime, and at the end
of exercise (Figure 4). With aclidinium treatment, im-
provements from baseline in IC were seen for every 2-min
interval during the first 10 min of exercise at Week 3
(range: 79 mL to 132 mL; Additional file 3). In contrast,
IC decreased compared with baseline for each corre-
sponding period in the placebo group (range −16 mL
to −110 mL; Additional file 3). Aclidinium significantly
improved IC compared with placebo at each interval from
0 to 8 min; there was no significant difference at 8–10 min.
Consistent with improvements in dynamic IC, EELV at
Week 3 was also reduced compared with baseline dur-
ing exercise with aclidinium 400 μg BID (Figure 5). Re-
ductions in EELV were observed at rest, at isotime, and
at the end of exercise. In contrast, there was no change
from baseline in EELV at Week 3 with placebo.
Throughout the study, only two patients did not
reach 85% SpO2 during exercise, suggesting that oxygen
desaturation was unlikely to be a major contributor to
exercise limitation in these patients.Static lung function and hyperinflation
After 3 weeks, aclidinium significantly increased trough
IC from baseline versus placebo (Δ= 78 mL; 95% CI 10, 145;
p < 0.05; Table 2). Other parameters of static lung
function were also significantly increased from baseline
with aclidinium versus placebo (Table 2).
Mean trough FRC, RV, and sGaw were significantly
improved from baseline with aclidinium versus placebo at
Week 3 (Table 2). The mean change from baseline in
trough IC:TLC ratio was 0.016 with aclidinium and
0.002 with placebo (Δ = 0.014; p < 0.01). At Week 3,
significant improvements from baseline with aclidinium
Figure 2 Patient disposition. BID, twice daily; ITT, intent-to-treat.
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RV, TLC, and sGaw (Table 2).
When assessed across the placebo and aclidinium
treatment periods, there was a weak negative correl-
ation between changes from baseline in endurance
time and post-dose RV (r = −0.159; p < 0.05), post-dose
FRC (r = −0.175; p = 0.01), and trough FRC (r = −0.144;
p < 0.05), and a weak positive correlation between
changes from baseline in endurance time and IC at rest
(r = 0.231; p < 0.001). There was no significant correlation
between changes in endurance time and trough RV and
trough IC. In the aclidinium treatment period, correlations
between lung volumes and endurance time were weak and
did not reach statistical significance.
Physical activity and symptoms
Changes from baseline in physical activity, as measured by
duration of activity of at least moderate intensity and daily
active energy expenditure, were significantly increased with
aclidinium versus placebo at Week 3 (Table 3). Numeric
increases in step count and physical activity level were also
observed with aclidinium versus placebo but did not reach
significance (Table 3).
When assessed across both treatments, there was no
significant correlation between changes from baseline in
step count or moderate activity and changes from baselinein endurance time (Table 4). Improvements in physical
activity parameters were related, and changes from
baseline in endurance time were negatively correlated with
changes in dyspnea at isotime (Table 4). As shown in
Additional file 4, similar results were observed during the
aclidinium period only.
Over 3 weeks there was a significant increase in relief
medication-free days with aclidinium versus placebo (6.3%
vs 20.9%; Δ = 14.6%; p < 0.0001). Reductions in number of
nocturnal awakenings due to COPD symptoms were
small and there was no significant difference between
treatments (p = 0.46).
Treatment effect by baseline PAL
Post-hoc analyses assessed change from baseline in en-
durance time at Week 3 in patients categorized as ‘ex-
tremely inactive’ , ‘sedentary’ , and ‘at least moderately
active’ at baseline. Improvements in endurance time with
aclidinium compared with placebo were greatest in pa-
tients who were categorized as extremely inactive at
baseline (Figure 6a). While there were also improve-
ments in endurance time with aclidinium versus placebo
in patients who were sedentary at baseline, these im-
provements were not statistically significant.
When physical activity parameters were assessed, im-
provements with aclidinium versus placebo were generally
Table 1 Patient demographics and baseline characteristics (safety population)
Characteristic Patients (N = 112)
Age (years), mean (SD) 60.3 (8.1)
Gender (male), n (%) 76 (67.9)
Race (Caucasian/white), n (%) 112 (100.0)
Current smoker, n (%) 74 (66.1)
Smoking history (pack-years), mean (SD) 48.0 (25.0)
COPD duration (years), mean (SD) 8.8 (6.3)
Severity of airflow limitation,a n (%)
Moderate 80 (71.4)
Severe 32 (28.6)
Post-bronchodilator FEV1 (L) at screening
Mean (SD) 1.7 (0.5)
% predicted, mean (SD) 56.7 (11.6)
FRC at screening (L)
Mean (SD) 5.0 (1.0)
% predicted, mean (SD) 152.3 (26.0)
Exercise endurance time at baselineb (s), mean (SD) 485.7 (234.4)
Intensity of dyspnea at isotime at baselineb (Borg CR-10 scale), mean (SD) 5.7 (2.6)
Lung function variables at baseline,b mean (SD)
FEV1 (L) 1.5 (0.5)
% predicted FEV1 49.7 (14.7)
FVC (L) 3.3 (0.9)
% predicted FVC 88.3 (18.2)
IC (L) 2.2 (0.5)
Whole-body plethysmographic variables at baseline,b mean (SD)
FRC (L) 5.0 (1.1)
% predicted FRC 151.3 (28.0)
RV (L) 4.0 (1.0)
% predicted RV 179.4 (40.5)
TLC (L) 7.3 (1.3)
% predicted TLC 116.9 (15.6)
sGaw (s−1kPa−1) 0.5 (0.3)
Physical activity variables at baseline,c mean (SD)
Step count (steps per day) 7030.0 (3718.3)
Duration of activity of at least moderate intensityd (min/day) 92.3 (70.8)
Physical activity levele 1.514 (0.216)
Daily active energy expenditure >3 metabolic equivalents (kcal/day) 451.1 (372.6)
aGOLD Stage 2 (moderate): FEV1/FVC <0.70, and post-bronchodilator FEV1 ≥50% and <80% predicted; GOLD Stage 3 (severe): FEV1/FVC <0.70, and post-bronchodilator
FEV1 ≥30% and <50% predicted.
bPre-dose at Visit 1.
cMean data for 7-day period prior to Visit 1 (patients who had ≥5 days with ≥22 h of valid data; n = 92).
dAny physical activity >3 metabolic equivalents.
eRatio calculated as the total daily energy expenditure divided by the whole of the night sleeping energy expenditure.
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FRC, functional residual capacity; FVC, forced vital capacity; GOLD, Global
initiative for chronic Obstructive Lung Disease; IC, inspiratory capacity; RV, residual volume; SD, standard deviation; sGaw, specific airway conductance; TLC, total
lung capacity.
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Figure 3 Change from baseline in exercise endurance time at
Week 3. Change from baseline in exercise endurance time during
constant work rate cycle ergometry to symptom limitation at 75% of
the maximum work rate was assessed at Week 3 (ITT population).
Data reported as least squares means change from baseline (analysis
of covariance) + standard error; Δ = least squares means difference
(95% confidence interval). *p < 0.05 versus placebo. BID, twice daily;
ITT, intent-to-treat.
Figure 4 Change from baseline in dynamic IC at end of exercise at W
at isotime, and at end of exercise was assessed at Week 3 (ITT population).
of covariance) + standard error; Δ = least squares means difference (95% co
daily; IC, inspiratory capacity; ITT, intent-to-treat.
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baseline (Figure 6). In these patients, the improvement in
daily step count was significantly greater with aclidinium
versus placebo (Figure 6).
Safety
The incidence of AEs was higher with aclidinium (44.1%)
than with placebo (30.6%). The most common AEs were
nasopharyngitis, headache, and abnormal (bitter) product
taste; each reported by a higher proportion of patients re-
ceiving aclidinium (6.3%, 4.5%, and 3.6%, respectively)
than placebo (3.7%, 2.8%, and 1.9%, respectively). There
were few discontinuations due to AEs following aclidi-
nium and placebo (3.6% and 1.9%, respectively). No ser-
ious AEs occurred during treatment with aclidinium.
There were no clinically relevant changes in hematology
or biochemistry parameters, or in other safety variables.
Discussion
The results of this study show that after 3 weeks, aclidi-
nium 400 μg BID significantly reduced the intensity of ex-
ertional dyspnea and improved cycling exercise endurance
compared with placebo. As lung hyperinflation is believed
to be an important factor contributing to reduced exercise
capacity in COPD [5-8], we believe the main driver of in-
creased exercise endurance was the consistent effect of
aclidinium treatment on lung volumes, as reflected by sig-
nificant improvements in static IC, FRC, RV, and TLC, as
well as dynamic IC during exercise.
The improvement in endurance time observed with
aclidinium was similar to that observed previously witheek 3. Change from baseline in dynamic IC measured before exercise,
Data reported as least squares means change from baseline (analysis
nfidence intervals). ***p < 0.001, ****p < 0.0001 versus placebo. BID, twice
Figure 5 EELV during exercise at baseline and at Week 3. EELV during constant work rate cycle ergometry in patients receiving a) placebo,
or b) aclidinium 400 μg BID. EELV was assessed at rest, at isotime, and at end of exercise at baseline and at Week 3 (ITT population). Data are
descriptive and reported as mean ± standard deviation. EELV was assessed as IC subtracted from mean TLC 2 h post-dose. Mean isotime was
calculated as 386 seconds. BID, twice daily; EELV, end-expiratory lung volumes; IC, inspiratory capacity; ITT, intent-to-treat; TLC, total lung capacity.
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with glycopyrrolate 50 μg QD (89 s) [13]. Improvements,
versus placebo, in IC at isotime (a marker of dynamic
hyperinflation) were also similar between aclidinium
400 μg BID (155 mL), tiotropium 18 μg QD (180–190 mL)
[10,22], and glycopyrrolate 50 μg QD (200 mL) [13]. Fur-
thermore, the improvement in static lung function (IC at
rest) with aclidinium (176 mL) was also comparable to that
provided by other LAMAs (180–220 mL) [10,13,22].
It has been proposed that a minimal clinically important
difference for exercise endurance time is in the range
46–105 s [23,24]; however, these estimates are based on
few studies and do not take into account the large vari-
ation in, for example, interventions, study methodology/
duration, patient characteristics and disease severity, andexercise testing protocols. Furthermore, it is unclear if
a change observed with a pulmonary rehabilitation pro-
gram involving regular training units is comparable to
what can be achieved with bronchodilators. Neverthe-
less, most published improvements in cycling endur-
ance with bronchodilators are in line with the proposed
range. We therefore believe that the improvements
seen with aclidinium fit well with the published data
and indicate a meaningful response.
In the present study, there was a correlation between
improvements in endurance time and reduced exertional
dyspnea, overall and in the aclidinium treatment period
only. Overall, improvements in endurance time were
also correlated with reduced post-dose RV and FRC and
increased IC at rest. There was no significant correlation
Table 2 Changes from baseline in lung function and body plethysmography parameters at Week 3 (ITT population)
Parameter Placebo (N = 108) Aclidinium 400 μg BID (N = 109) Treatment difference vs placebo (95% CI)
Pre-dose (trough) IC (mL) 20 (25) 98 (24) 78 (10, 145)*
Pre-dose (trough) FEV1 (mL) −25 (21) 108 (21) 132 (74, 191)
****
Pre-dose (trough) FVC (mL) −46 (31) 198 (30) 243 (157, 329)****
FRC (mL)
Pre-dose (trough) 15 (39) −182 (39) −197 (−321, −72)**
Post-dose −130 (46) −449 (46) −318 (−448, −189)****
RV (mL)
Pre-dose (trough) 15 (60) −222 (60) −238 (−396, −79)**
Post-dose −81 (57) −523 (57) −443 (−599, −286)****
TLC (mL)
Pre-dose (trough) −6 (41) −82 (41) −76 (−201, 49)
Post-dose −49 (41) −199 (41) −150 (−262, −37)**
sGaw (s−1kPa−1)
Pre-dose (trough) 0.002 (0.020) 0.096 (0.020) 0.094 (0.038, 0.150)**
Post-dose 0.054 (0.027) 0.297 (0.026) 0.243 (0.182, 0.303)****
Data reported as least squares means (standard error) change from baseline (analysis of covariance).
*p < 0.05, **p < 0.01, ****p < 0.0001 versus placebo.
BID, twice daily; CI, confidence interval; FEV1, forced expiratory volume in 1 s; FRC, functional residual capacity; FVC, forced vital capacity; IC, inspiratory capacity;
ITT, intent-to-treat; RV, residual volume; sGaw, specific airway conductance; TLC, total lung capacity.
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endurance time when assessed in the aclidinium treat-
ment period only. To the best of our knowledge, only one
previous study has investigated the relationship between
exercise endurance time and lung volumes following treat-
ment with a LAMA in patients with COPD [10]. While a
correlation between endurance time and exertional dys-
pnea and between endurance time and dynamic IC was
observed following treatment with tiotropium 18 μg; the
relationship between endurance time and static lung vol-
umes was not reported [10]. Furthermore, patients were
treated with tiotropium 18 μg for 6 weeks compared with
the shorter 3-week treatment period with aclidinium in
the present study.
Aclidinium treatment also significantly improved the
duration of activity of moderate intensity and daily energyTable 3 Changes from baseline in physical activity parameter
Parameter Pla
(n =
Step count (steps per day) −163.2
Duration of activity of at least moderate intensityb (min/day) −5.9
Physical activity levelc −0.006
Daily active energy expenditure >3 metabolic equivalents (kcal/day) −32.7
Data reported as least squares means (standard error) change from baseline (analys
*p < 0.05 versus placebo.
an = number of patients who had ≥5 days with ≥22 h of valid data and were includ
bAny physical activity >3 metabolic equivalents.
cRatio calculated as the total daily energy expenditure divided by the whole of the
dn = 84.
BID, twice daily; CI, confidence interval; ITT, intent-to-treat.expenditure. It is difficult to speculate on the clinical rele-
vance of the improvement in the duration of moderate
physical activity observed with aclidinium (10 min vs pla-
cebo). Recently, a prospective cohort study reported the
health benefits of 15 min moderate physical activity per
day in terms of mortality reduction in the general popula-
tion [25]. Furthermore, physical activity level has been
found to be a strong predictor of mortality in patients with
COPD [26,27]. Further studies are needed to link im-
provements in physical activity in COPD to other patient-
centered outcomes, and ideally, to also demonstrate health
benefits in terms of reduced morbidity and mortality.
In the present study, there was no correlation between
improved endurance time and increased physical activity
in the whole study population and following treatment
with aclidinium. This might be based on the observations at Week 3 (ITT population)
cebo
83a)
Aclidinium 400 μg BID
(n = 85a)
Treatment difference vs placebo
(95% CI)
(226.1) 295.8 (223.7) 459.0 (−61.8, 979.8)
(4.1) 4.2 (4.1) 10.1 (2.0, 18.2)*
(0.013) 0.018 (0.013)d 0.024 (−0.003, 0.051)
(21.0) 21.9 (20.8) 54.5 (13.3, 95.8)*
is of covariance).
ed in the analyses.
night sleeping energy expenditure.
Table 4 Relationship between physical activity, endurance time, and exertional dyspnea
Observationsa Correlation P-value
Change from baseline in daily step countb Change from baseline in endurance time (s) 168 0.061 0.433
Change from baseline in duration of at least
moderate activity (min)b
168 0.640 <0.0001
Change from baseline in duration of at least
moderate activity (min/day)b
Change from baseline in endurance time (s) 168 −0.015 0.845
Change from baseline in endurance time (s) Change from baseline in exertional dyspnea at isotime 216 −0.535 <0.0001
Pearson correlation for change from baseline in mean daily step count, mean duration of at least moderate activity (>3 metabolic equivalents), endurance time
during constant work rate cycle ergometry to symptom limitation at 75% of the maximum work rate, and exertional dyspnea at isotime across the study
(aclidinium and placebo treatment periods; ITT population).
aNumber of observations used to calculate the correlation.
bPatients who had ≥5 days with ≥22 h of valid data.
ITT, intent-to-treat.
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http://www.biomedcentral.com/1471-2466/14/209that patients in this study who were extremely inactive
at baseline had the greatest improvements in endurance
time, whereas patients who were sedentary at baseline
had the greatest improvements in physical activity.
While the analyses reported here were exploratory, andFigure 6 Changes from baseline in exercise endurance and physical a
baseline in a) exercise endurance time during constant work rate cycle erg
b) daily step count, c) duration of moderate activity >3 metabolic equivale
baseline physical activity levels (inactive, sedentary, or at least moderately a
from baseline (analysis of covariance) + standard error; Δ = least squares me
each subgroup included in the analyses. *p < 0.05 versus placebo. BID, twicin the case of the baseline PAL analyses, performed in
small numbers of patients, they expand previous studies
that suggest factors other than increased capacity are in-
volved in driving patients with COPD to become more
physically active.ctivity at Week 3, by baseline physical activity. Changes from
ometry to symptom limitation at 75% of the maximum work rate,
nts, and d) energy expenditure at Week 3 were assessed according to
ctive; ITT population). Data reported as least squares means change
ans difference (95% confidence intervals). n = number of patients in
e daily; ITT, intent-to-treat.
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http://www.biomedcentral.com/1471-2466/14/209Study limitations might include the short treatment
duration, absence of assessments beyond 3 h post-dose
to determine duration of effect, and the lack of an active
comparator. Nevertheless, this study provides useful data
to supplement findings from previous Phase III studies,
demonstrating that aclidinium significantly improved
lung function and symptoms versus placebo over 12 and
24 weeks and had comparable 24-h bronchodilatory effi-
cacy to tiotropium over 6 weeks in patients with COPD
[28-30]. Aclidinium has also been demonstrated to be
safe and well tolerated in patients with COPD [29,30],
and the safety findings from this short study were
consistent with those previously observed.
Conclusions
Treatment with aclidinium 400 μg BID significantly im-
proved exercise endurance and related exertional dyspnea,
and lung hyperinflation compared with placebo over 3 weeks
in patients with stable COPD and moderate-to-severe
airflow limitation. Aclidinium also provided significant
improvements in static lung function and lung volumes,
and parameters of physical activity compared with placebo.
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aRegistered trademarks of AstraZeneca PLC, Barcelona,
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within all other licensed territories.
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